- Report
- January 2026
- 197 Pages
Global
From €3153EUR$3,545USD£2,722GBP
€3503EUR$3,939USD£3,025GBP
- Report
- January 2026
- 196 Pages
Global
From €3153EUR$3,545USD£2,722GBP
€3503EUR$3,939USD£3,025GBP
- Report
- February 2026
- 250 Pages
Global
From €3993EUR$4,490USD£3,448GBP
- Report
- May 2026
- 299 Pages
Global
From €5202EUR$5,850USD£4,492GBP
- Report
- February 2026
- 306 Pages
Global
From €2223EUR$2,500USD£1,920GBP
- Report
- October 2025
- 160 Pages
Global
From €2986EUR$3,358USD£2,578GBP
€3513EUR$3,950USD£3,033GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,216USD£3,128GBP
- Report
- February 2026
- 250 Pages
Global
From €3993EUR$4,490USD£3,448GBP
- Report
- June 2025
- 150 Pages
Global
From €3335EUR$3,750USD£2,880GBP
- Report
- June 2025
- 150 Pages
Global
From €2400EUR$2,699USD£2,073GBP
- Report
- February 2026
- 250 Pages
Global
From €3993EUR$4,490USD£3,448GBP
- Report
- February 2026
- 250 Pages
Global
From €3993EUR$4,490USD£3,448GBP
- Report
- May 2026
- 389 Pages
Global
From €5202EUR$5,850USD£4,492GBP
- Report
- January 2026
- 185 Pages
Global
From €4002EUR$4,500USD£3,456GBP
- Report
- July 2025
- 350 Pages
Global
From €4401EUR$4,949USD£3,800GBP
- Report
- October 2025
- 160 Pages
Global
From €2986EUR$3,358USD£2,578GBP
€3513EUR$3,950USD£3,033GBP
- Report
- August 2025
- 200 Pages
United States
From €2214EUR$2,490USD£1,912GBP
- Report
- May 2025
- 200 Pages
Global
From €2214EUR$2,490USD£1,912GBP
- Report
- August 2024
- 200 Pages
Global
From €2214EUR$2,490USD£1,912GBP
- Clinical Trials
- April 2025
- 220 Pages
Global
From €2223EUR$2,500USD£1,920GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more